Scientists examined nine biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis for whom prior pharmacological treatment had failed. According to the findings, for each drug the data provided proof, an indication, or at least a hint of a benefit in relation to at least one outcome criterion.